u/rekha_vestergaard

Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.

customs clearance time is not carrier time and they get conflated

What has been documented as tried, and for how long?

A quoted lead time is a commitment you can evaluate. Measuring quoted against actual across several orders tells you more about an operation than the raw speed does.

Sent a vial to Medutest out of curiosity. Result was 97.6% against a claimed 97.0%, which is the first independent number I had seen for this compound anywhere.

small trial, big effect, wide error bars

I would not read a single slow shipment as a lane change. Post it and let the median move if it is real.

a lane with four reports is not yet a lane

Correcting my own answer earlier — I said week 22 and the wiki says week 3. The wiki is right.

Is this your first step up or the starting dose?

research-use-only material is not approved for human use, and that belongs in every beginner thread

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

regional stock changes everything about transit

Have you asked for the clinical policy bulletin by number?

Same. TFC quoted 14 days on my lane and it landed at 4, which is exactly what you want from a quote.

Disagree with the tone strategy. Anger has never moved a determination; matching the criterion has.

Have you asked for the clinical policy bulletin by number?

This.

ruben_cabrera has explained this better than the wiki does, which is saying something.

New plan year, entirely new criteria, and the denial that had been immovable in the autumn simply did not apply in January.

Concentration is mass over volume, and a U-100 syringe reads 100 units per millilitre. Those two facts are the whole of the arithmetic this board keeps explaining.

Asked what a COA was in my first week. Somebody linked the explainer and I have been reading them ever since.

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

the glucagon component is why the metabolic story reads differently

Are you comparing against phase 3 numbers for something else? They are not comparable.

Step therapy requires documented trial of preferred alternatives. It is not an argument to be won on merits; it is a record to be produced, and the record is what the appeal must contain.

Disagree with the tone strategy. Anger has never moved a determination; matching the criterion has.

I would not skip the peer-to-peer. It is often the fastest route and it costs a phone call.

a quoted lead time you can hold them to is worth more than a fast one you cannot

research-use-only material is not approved for human use, full stop

Gently disagree with the framing — nothing has gone wrong. Week 22 looking flat is the ordinary experience.

heart rate is the thing people report watching

Did you write the concentration on the vial?

Four observations is not a distribution.

Adding the field everyone forgets — the month. Without it the report is not comparable to anything.

Push back: comparing a July transit with a February one on the same lane is not a comparison.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Cosigning the wiki point, and also: ask anyway. The wiki cannot tell you it understood your question.

the lane is the unit of analysis, not the supplier

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.

the denial letter names the criterion, start there

Correcting myself upthread: the deadline was 2 days, not the figure I gave.